Skip to main content
letter
. 2020 Sep;152(3):316–319. doi: 10.4103/ijmr.IJMR_1498_18

Table.

Comparison between starters and non-starters of medication (pre-treatment attrition) and between those who discontinued and continued the medication

Pre-treatment attrition (n=35)

Parameters Mean±SD/frequency

Non-starters (n=8) Starters (n=27)
Age (yr) 9.62±3.58 10.29±3.75
Gender (male), n (%) 8 (100) 23 (85.2)
IQ 92.12±13.26 81.89±19.61
Presence of ID 1 (12.5) 7 (26)
Baseline symptom severity 35.16±7.18 38.07±9.15
Presence of comorbidity 1 (12.5) 10 (37.03)
Family type (joint) 7 (87.5) 9 (33.34)**
Discontinuation among those who started medication (n=27)

Parameters Mean±SD/frequency

Discontinuers (n=12) Continuers (at the end of study) (n=15)

Age (yr) 10.00±2.92 10.53±2.69
Gender (male), n (%) 10 (83.34) 13 (86.67)
IQ 74.92±19.13 87.60±18.60
Presence of ID 6 (50) 1 (6.67)*
Baseline symptom severity 36.42±8.13 39.40±9.97
Presence of comorbidity 4 (33.34) 6 (40)
Presence of ASD 3 (25) 0 (0)
Presence of severe side effects 4 (33.34) 0 (0)*
Family type (joint) 4 (33.34) 5 (33.34)

Values in parentheses are percentages. P*<0.05, **<0.01 compared to respective group. ID, intellectual disability; IQ, intellectual quotient; ASD, autism spectrum disorder